Anti-FGFR2 antibodies and methods of use thereof
US11866502B2 · kind B2 · utility
0Cited by
10References
65Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2021 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Nov 27, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.